Validity and Inter-Rater Reliability of a Novel Bedside Referral Tool for Spasticity
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
Tennessee
-
Murfreesboro, Tennessee, United States, 37130
- Tennessee State Veterans' Homes
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Males or female subjects of any race, aged 18 and above
- Resident of the selected long-term care facility
- The subject, or if appropriate their medical decision maker, is willing and able to provide written informed consent.
Exclusion Criteria:
- Subjects for whom participation in the study may cause medical harm
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Sensitivity of Bedside Referral Tool
Time Frame: Up to three months after consent is obtained
|
Two Vanderbilt primary care providers (a nurse practitioner and a primary care physician) will examine all consented residents, guided by the bedside referral tool, to determine if a referral to a movement disorders neurologist is requires for a spasticity consultation.
The findings of each exam will be recorded by the research coordinator, who will keep the results blinded from the other raters.
Each rater's referral decision will be compared to the diagnosis made by the movement disorders neurologist.
|
Up to three months after consent is obtained
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Spasticity Diagnosis
Time Frame: Up to three months after consent is obtained
|
There is no biomarker for spasticity.
Therefore, the diagnosis will be made on physician impression.
A neurologist trained in movement disorders will examine each consented patient to determine if they have spasticity.
The severity of the subject's spasticity will be documented, including the following measures: presence of fixed contractures and presence of pain on movement.
|
Up to three months after consent is obtained
|
|
Specificity of Bedside Referral Tool
Time Frame: Up to three months after consent is obtained
|
Two Vanderbilt primary care providers (a nurse practitioner and a primary care physician) will examine all consented residents, guided by the bedside referral tool, to determine if a referral to a movement disorders neurologist is requires for a spasticity consultation.
The findings of each exam will be recorded by the research coordinator, who will keep the results blinded from the other raters.
Each rater's referral decision will be compared to the diagnosis made by the movement disorders neurologist.
|
Up to three months after consent is obtained
|
|
Inter-rater Reliability
Time Frame: Up to three months after consent is obtained
|
Two Vanderbilt primary care providers (a nurse practitioner and a primary care physician) will examine all consented residents, guided by the bedside referral tool, to determine if a referral to a movement disorders neurologist is requires for a spasticity consultation.
The findings of each exam will be recorded by the research coordinator, who will keep the results blinded from the other raters.
Agreement on spasticity referral between the two Vanderbilt primary care providers who performed the bedside examination will be determined.
|
Up to three months after consent is obtained
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: David Charles, M.D., Professor and Vice-Chairman of Neurology
Publications and helpful links
General Publications
- Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1977 Mar;33(1):159-74.
- Gracies JM. Pathophysiology of spastic paresis. II: Emergence of muscle overactivity. Muscle Nerve. 2005 May;31(5):552-71. doi: 10.1002/mus.20285.
- Thompson AJ, Jarrett L, Lockley L, Marsden J, Stevenson VL. Clinical management of spasticity. J Neurol Neurosurg Psychiatry. 2005 Apr;76(4):459-63. doi: 10.1136/jnnp.2004.035972. No abstract available.
- Pfister AA, Roberts AG, Taylor HM, Noel-Spaudling S, Damian MM, Charles PD. Spasticity in adults living in a developmental center. Arch Phys Med Rehabil. 2003 Dec;84(12):1808-12. doi: 10.1016/s0003-9993(03)00368-x.
- Sommerfeld DK, Eek EU, Svensson AK, Holmqvist LW, von Arbin MH. Spasticity after stroke: its occurrence and association with motor impairments and activity limitations. Stroke. 2004 Jan;35(1):134-9. doi: 10.1161/01.STR.0000105386.05173.5E. Epub 2003 Dec 18.
- Welmer AK, von Arbin M, Widen Holmqvist L, Sommerfeld DK. Spasticity and its association with functioning and health-related quality of life 18 months after stroke. Cerebrovasc Dis. 2006;21(4):247-53. doi: 10.1159/000091222. Epub 2006 Jan 27.
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 162074
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Nervous System Diseases
-
NCT02291822CompletedCentral Nervous System Neoplasms | Central Nervous System Disease
-
NCT07435649Not yet recruiting
-
NCT03147989CompletedCentral Nervous System Diseases | Central Nervous System Neoplasms
-
NCT03750188CompletedCentral Nervous System Diseases | Central Nervous System Neoplasms
-
NCT02385877CompletedAutonomic Peripheral Nervous System Diseases
-
NCT05978557RecruitingCentral Nervous System Tumor
-
NCT02559752Recruiting
-
NCT01804192UnknownAutonomic Nervous System Disorder
-
NCT01004887CompletedBrain and Central Nervous System Tumors
-
NCT00019071CompletedBrain and Central Nervous System Tumors
Clinical Trials on Bedside Referral Tool
-
NCT04584203RecruitingCritical Illness | Mechanical Ventilation Complication | Weaning Failure | Diastolic Heart Failure | Diastolic Dysfunction
-
NCT02714582CompletedPatient Participation | Nursing | Bedside Shift Report
-
NCT04179695Recruiting
-
NCT00961727CompletedClinically Deteriorating Paediatric Patients
-
NCT02976415CompletedCritical Illness | Critical Illness Myopathy | Thoracic Surgery | Cardiac Disease | Critical Illness Polyneuropathy
-
NCT07281638Not yet recruitingDelirium | Fall | Deep Venous Thrombosis | Mobility Limitation | Hospital Acquired Condition | Immobility Syndrome
-
NCT03632486Completed
-
NCT03279588CompletedAbdominal Pain | Acute Diverticulitis
-
NCT03469466Unknown